Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Gastric cancer marker and application thereof

A gastric cancer and drug technology, applied in the field of tumor molecular biology, can solve the problems of changing cancer signal transduction and affecting the tumor microenvironment, limited function, unclear neoadjuvant chemotherapy, etc.

Active Publication Date: 2019-12-24
BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a significant proportion of GC patients do not respond well to neoadjuvant chemotherapy
To date, only certain clinical characteristics, such as age and preoperative weight loss, are available for patient selection, but with very limited functionality
Furthermore, it is unclear how neoadjuvant chemotherapy alters cancer signaling and affects the tumor microenvironment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gastric cancer marker and application thereof
  • Gastric cancer marker and application thereof
  • Gastric cancer marker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] Hereinafter, the present invention is described in more detail to facilitate understanding of the present invention.

[0022] Patient Recruitment and Sample Cohorts

[0023]GC patients (>T2N+M0, UICC-AJCC 8th edition) for this inventive study were recruited at Peking University Cancer Hospital (Beijing, China) from 2015 to 2018. The study was performed in accordance with the Statement of Helsinki and was approved by the Ethics Committee of Peking University Cancer Hospital (IRB approval number, 2019KT05). All patients provided written informed consent prior to treatment, sample collection, and analysis. Tumors were collected by biopsy and matched to adjacent nontumor tissue before neoadjuvant therapy. For patients with no adjacent non-neoplastic tissue available, blood samples were taken instead. Then, all patients received a fluorouracil-based capecitabine / S-1+oxaliplatin regimen (XELOX [oxaliplatin, 130 mg / m2, intravenous injection, day 1; capecitabine, 1000 mg / m2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a gastric cancer marker and application thereof, in particular to application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in the preparation of a product for predicting the response of a GC patient to neoadjuvant chemotherapy. It is determined for the first time that C10orf71 gene mutation is a key molecular feature withcancer in response to neoadjuvant chemotherapy. Based on the technical scheme, neoadjuvant chemotherapy has advantages in improving prognosis and determining responsive patients before treatment begins, and better therapeutic schemes can be developed. The scheme is an important step for optimizing therapeutic strategies for individual patients with GC.

Description

technical field [0001] The invention relates to the field of tumor molecular biology, in particular to a gastric cancer cancer marker and its application. Background technique [0002] Gastric cancer (GC) is one of the most common cancer types worldwide and the second most common cause of cancer-related death (8.2%). China is the country with the largest number of GC patients, with over 679,000 newly diagnosed GC cases and approximately 498,000 GC-related deaths occurring annually, according to the Chinese National Central Cancer Registry. Most of these patients are at an advanced stage, and their 5-year survival rate is <30%. Although surgical treatment is the main treatment for GC, multimodal strategies are still employed to improve patient survival. Neoadjuvant (or perioperative) chemotherapy can "reduce the size of the tumor" before a radical resection is attempted. Furthermore, for GC patients at high risk of developing distant metastases, neoadjuvant chemotherapy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/106C12Q2600/156C12Q2600/118
Inventor 季加孚李子禹高翔宇季序我梁晗彭鑫鑫李哲魏斌韦宝耶董宇
Owner BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com